ONO will be conducting a series of clinical trials in Japan to assess the safety and efficacy of using OPDIVO for a wide range of additional indications, including head and neck cancer.
Japan-based company sponsor, ONO Pharmaceutical, is expanding its use of Medidata’s Clinical Cloud to evaluate additional indications for OPDIVO, a cutting-edge immunotherapy drug in Japan. ONO will be conducting a series of clinical trials in Japan to assess the safety and efficacy of using OPDIVO for a wide range of additional indications, including head and neck cancer.
A Medidata customer since 2012, ONO utilizes Medidata Rave to support its Phase II and III clinical trials in oncology, cancer anorexia/cachexia and diabetes.
